I-Mycobacterium Tuberculosis Nucleic Acid kunye ne-Rifampicin(RIF),Ukumelana(INH)
Igama lemveliso
HWTS-RT147 Mycobacterium Tuberculosis Nucleic Acid and Rifampicin(RIF), (INH) Ikhithi yokuFumana (Ijika elinyibilikayo)
I-Epidemiology
I-Mycobacterium tuberculosis, kungekudala njenge-Tubercle bacillus (TB), yibhaktiriya ye-pathogenic ebangela isifo sephepha, kwaye ngoku, amayeza achasene nesifo sephepha asetyenziswa ngokuxhaphakileyo aquka isoniazid, rifampicin kunye ne-ethambutol, njl.[1]. Nangona kunjalo, ngenxa yokusetyenziswa kakubi kweziyobisi ezichasene nesifo sephepha kunye neempawu zesakhiwo sodonga lweseli ye-mycobacterium tuberculosis ngokwayo, isifo sephepha se-mycobacterium siye savelisa ukuxhathisa amachiza kumachiza alwa nesifo sephepha, kwaye uhlobo oluyingozi kakhulu lwesifo sephepha esinganyangekiyo ngamachiza (MDR-TB), esinganyangekiyo kumachiza amabini aqhelekileyo kwaye asebenzayo, i-rifampicin kunye ne-rifampicin.[2].
Ingxaki yokunganyangeki kwamachiza esifo sephepha ikhona kuwo onke amazwe avavanywe yi-WHO. Ukuze kubonelelwe ngezicwangciso zonyango ezichaneke ngakumbi kwizigulana zesifo sephepha, kuyimfuneko ukubona ukuxhathisa kumachiza alwa nesifo sephepha, ngakumbi ukunganyangeki kwe-rifampicin, okuye kwaba linyathelo loxilongo elicetyiswa yi-WHO kunyango lwesifo sephepha.[3]. Nangona ukufunyanwa kokunganyangeki kwe-rifampicin kuphantse kulingane nokufunyaniswa kwe-MDR-TB, ukufumanisa kuphela ukunganyangeki kwe-rifampicin kukungahoyi izigulane ezine-mono-resistant INH (ibhekisa ekuchaseni i-isoniazid kodwa uvakalelo kwi-rifampicin) kunye ne-mono-resistant rifampicin (uvakalelo kwi-isoniazid kodwa ukunganyangeki kwi-rifampicin), nto leyo enokukhokelela ekubeni izigulane zibe nonyango olungenangqiqo ekuqaleni. Ngoko ke, uvavanyo lokuxhathisa i-isoniazid ne-rifampicin zizinto eziyimfuneko ezifunekayo kuzo zonke iinkqubo zolawulo lwe-DR-TB[4].
Iiparamitha zobuGcisa
Ugcino | ≤-18℃ |
Beka ubomi kwishelufa | Iinyanga ezili-12 |
Uhlobo loMfanekiso | Isampulu yesikhohlela, iNkcubeko eZinzi (LJ Medium), iNkcubeko yoLwalo (MGIT Medium) |
CV | <5.0% |
LoD | I-LoD yekhithi yokubona i-Mycobacterium tuberculosis yibhaktiriya eli-10/mL;i-LoD yekhithi yokukhangela uhlobo lwasendle lwe-rifampicin kunye nohlobo oluguqukileyo li-150 ibhaktiriya/mL; i-LoD yekhithi yokukhangela uhlobo lwasendle lwe-isoniazid kunye nohlobo oluguqukayo ngama-200 ebhaktiriya/mL. |
Ukuchaza ngokuthe ngqo | I-1) Akukho ukusabela okunqamlezileyo xa usebenzisa ikiti ukuze ufumane i-DNA ye-genomic yabantu (500ng), ezinye iintlobo ze-28 zentsholongwane yokuphefumula, kunye ne-29 yeentlobo ze-mycobacteria ezingekho tuberculous (njengoko kuboniswe kwiThebhile 3).2) Akukho mpendulo inqamlezayo xa usebenzisa ikiti ukukhangela iziza zotshintsho zezinye iijini ezingevayo ngamachiza e-rifampicin kunye ne-isoniazid enovakalelo lwe-Mycobacterium tuberculosis (njengoko kubonisiwe kwiTheyibhile yesi-4).I-3) Izinto eziphazamisayo eziqhelekileyo kwiisampuli eziza kuvavanywa, ezifana ne-rifampicin (9mg / L), isoniazid (12mg / L), i-ethambutol (8mg / L), i-amoxicillin (11mg / L), i-oxymetazoline (1mg / L), i-mupirocin (20mg / L), i-pyrazinamide (45mg / L), i-pyrazinamide (45mg / L) (20mg/L) iziyobisi, azinampembelelo kwiziphumo zovavanyo lwekhithi. |
Izixhobo Ezisebenzayo | SLAN-96P Iinkqubo zePCR zeXesha lokwenyani (Hongshi Medical Technology Co., Ltd.), I-BioRad CFX96 Inkqubo yePCR yexesha lokwenyani |